Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Brilinta (ticagrelor)
- rucaparib
Interactions between your drugs
ticagrelor rucaparib
Applies to: Brilinta (ticagrelor), rucaparib
MONITOR: Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4. In a clinical study, rucaparib increased midazolam Cmax and AUC by 1.13- and 1.38-fold, respectively.
MANAGEMENT: Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
References (1)
- EMA. European Medicines Agency. European Union (2013) EMA - List of medicines under additional monitoring. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Repatha
Repatha is used to lower high cholesterol alongside dietary changes and to reduce the risk of major ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Eliquis
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with ...
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Plavix
Plavix (clopidogrel) is used to prevent blood clots after a recent heart attack or stroke. Includes ...
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.